Dr. Adam Mitchell Spivak, MD

Dr. Spivak practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Spivak's NPI, 1528040433, was assigned on November 16, 2005. Dr. Spivak graduated from University of Maryland School of Medicine in 2002. Dr. Spivak holds Utah license 8111343-1205.

Dr. Spivak's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Spivak's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Spivak is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spivak practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Spivak's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Dr. Spivak's licenses on file in 2 states: Utah and Maryland.

CMS data shows 31 Medicare services from Dr. Spivak across 2 procedure codes in 2024, for 28 Medicare patients. Medicare paid $1,522 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 28 Medicare patients who saw Dr. Spivak in 2024. 68% of them have high blood pressure, and 46% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spivak's median patient age at 65, with 14% women.

In 2024, Dr. Spivak wrote 1,248 Medicare Part D claims for 65 patients. 66% of them were for generic drugs. CMS names the drug for 985 of them, across 37 drugs with 11 or more claims each, at $1,132,556 in total drug cost. In 2023, CMS named 422 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Spivak for performance year 2024, reported as part of a group. Dr. Spivak accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 61 papers to Dr. Spivak, published from 2011 to 2025. 2021 was the busiest year, with 9. The most frequent topics are HIV Infections, HIV-1 and Virus Latency. Dr. Spivak has published most often in AIDS Res Hum Retroviruses. Dr. Spivak's most frequent co-authors are Julio Cesar Delgado, MD, Joel Nee-Lartley Blankson, MD and David Robert Boulware, MD, MPH.

Dmand AI links Dr. Spivak to 1 clinical trial. Conditions studied include Acquired Immunodeficiency Syndrome and Slow Virus Diseases.

CMS Open Payments shows 5 general payments to Dr. Spivak from 3 drug and device companies from 2020 to 2021. Honoraria make up the largest share, 77% of the total. Horizon Pharma plc paid the most, $3,899.

Dr. Spivak graduated from University of Maryland School of Medicine in 2002.